Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H16ClNO4S |
Molecular Weight | 353.821 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC1=CC=C(CCNS(=O)(=O)C2=CC=C(Cl)C=C2)C=C1
InChI
InChIKey=IULOBWFWYDMECP-UHFFFAOYSA-N
InChI=1S/C16H16ClNO4S/c17-14-5-7-15(8-6-14)23(21,22)18-10-9-12-1-3-13(4-2-12)11-16(19)20/h1-8,18H,9-11H2,(H,19,20)
Daltroban (also known as BM 13505, SKF 96148), a specific thromboxane A2 receptor antagonist, was studied as an antithrombotic agent. The drug was licensed to Smith Kline Beecham, underwent phase III clinical trials in the UK and Germany as an antithrombotic agent but did not enter clinical trials in the USA. Besides, вaltroban was investigated in patients with an ischemic heart disorder. However, the development of daltroban has been discontinued.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3156 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10091692 |
37.1 nM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Protective effect of the specific thromboxane receptor antagonist, BM-13505, in reperfusion injury following acute myocardial ischemia in cats. | 1989 Apr |
|
Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets. | 1992 Jul |
|
Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022. | 1997 Jun 11 |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C169873
Created by
admin on Sat Dec 16 16:56:23 GMT 2023 , Edited by admin on Sat Dec 16 16:56:23 GMT 2023
|
PRIMARY | |||
|
BB-44
Created by
admin on Sat Dec 16 16:56:23 GMT 2023 , Edited by admin on Sat Dec 16 16:56:23 GMT 2023
|
PRIMARY | |||
|
100000083996
Created by
admin on Sat Dec 16 16:56:23 GMT 2023 , Edited by admin on Sat Dec 16 16:56:23 GMT 2023
|
PRIMARY | |||
|
SUB06893MIG
Created by
admin on Sat Dec 16 16:56:23 GMT 2023 , Edited by admin on Sat Dec 16 16:56:23 GMT 2023
|
PRIMARY | |||
|
79094-20-5
Created by
admin on Sat Dec 16 16:56:23 GMT 2023 , Edited by admin on Sat Dec 16 16:56:23 GMT 2023
|
PRIMARY | |||
|
6061
Created by
admin on Sat Dec 16 16:56:23 GMT 2023 , Edited by admin on Sat Dec 16 16:56:23 GMT 2023
|
PRIMARY | |||
|
54343
Created by
admin on Sat Dec 16 16:56:23 GMT 2023 , Edited by admin on Sat Dec 16 16:56:23 GMT 2023
|
PRIMARY | |||
|
m4075
Created by
admin on Sat Dec 16 16:56:23 GMT 2023 , Edited by admin on Sat Dec 16 16:56:23 GMT 2023
|
PRIMARY | Merck Index | ||
|
S25VDY08ZC
Created by
admin on Sat Dec 16 16:56:23 GMT 2023 , Edited by admin on Sat Dec 16 16:56:23 GMT 2023
|
PRIMARY | |||
|
DTXSID6046501
Created by
admin on Sat Dec 16 16:56:23 GMT 2023 , Edited by admin on Sat Dec 16 16:56:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL71685
Created by
admin on Sat Dec 16 16:56:23 GMT 2023 , Edited by admin on Sat Dec 16 16:56:23 GMT 2023
|
PRIMARY |
ACTIVE MOIETY